NEW YORK (GenomeWeb) – Agendia said today that it has received CE marking for its next-generation sequencing-based MammaPrint BluePrint kit for breast cancer recurrence risk testing and molecular subtyping, allowing the firm to commercialize the device in Europe.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.